BIOMAT Database Logo BIOMAT Database Logo

[Clinical experience with single and multiple subcutaneous administration of LHRH analog Buserelin (Hoe 766) in prostatic carcinoma: endocrinological study of optimum subcutaneous doses]. 1988

T Niijima, and K Isurugi, and K Kawabe, and K Kinoshita, and M Asano, and K Nakauchi, and K Fujita, and Y Nishimura, and H Nitoh, and M Yokoyama

Seventy three patients with prostatic carcinoma (PC) and 7 patients with benign prostatic hypertrophy (BPH) in 12 institutes subcutaneously received single and multiple doses of Hoe 766, and clinical efficacy, safety and endocrine effects of drug were examined. In a single doses study, six doses were subcutaneously administered to 7 BPH and 3 with PC. Gonadotropin and testosterone levels in the blood were increased following all these doses. In a multiple study, 7 kinds of doses were given to 40 patients with PC. The optimum doses of subcutaneous injection was decided to be 500 x 3 micrograms/day based on gonadotropin and testosterone suppression. Objective response by NPCP's criteria was observed in 35.3% (complete response 5.9%, partial response 29.4%) following 3 months of Hoe 766 treatment. Adverse reactions were observed in 9 cases (12.8%): Treatment was discontinued in 3 cases (eruption in 2, nausea and vomiting in 1), and continued in 6 cases (8.6%) without any treatment required. Buserelin was thus considered to be an effective, safe drug to treat prostatic carcinoma.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007986 Luteinizing Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. ICSH (Interstitial Cell Stimulating Hormone),Interstitial Cell-Stimulating Hormone,LH (Luteinizing Hormone),Lutropin,Luteoziman,Luteozyman,Hormone, Interstitial Cell-Stimulating,Hormone, Luteinizing,Interstitial Cell Stimulating Hormone
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D002064 Buserelin A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications. Bigonist,Buserelin Acetate,HOE-766,Profact,Receptal,Suprecur,Suprefact,Tiloryth,Acetate, Buserelin,HOE 766,HOE766
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation

Related Publications

T Niijima, and K Isurugi, and K Kawabe, and K Kinoshita, and M Asano, and K Nakauchi, and K Fujita, and Y Nishimura, and H Nitoh, and M Yokoyama
Investigations of the carcinogenicity of the LH-RH analog buserelin (HOE 766) in rats using the subcutaneous route of administration.
November 1987, Fundamental and applied toxicology : official journal of the Society of Toxicology,
T Niijima, and K Isurugi, and K Kawabe, and K Kinoshita, and M Asano, and K Nakauchi, and K Fujita, and Y Nishimura, and H Nitoh, and M Yokoyama
Complete response of lung metastases caused by prostatic cancer after chronic administration of a gonadotropin-releasing hormone analog, buserelin (HOE 766).
January 1987, The Prostate,
T Niijima, and K Isurugi, and K Kawabe, and K Kinoshita, and M Asano, and K Nakauchi, and K Fujita, and Y Nishimura, and H Nitoh, and M Yokoyama
The prolonged action of the LHRH agonist buserelin (HOE 766) may be due to prolonged binding to the LHRH receptor.
August 1986, Life sciences,
T Niijima, and K Isurugi, and K Kawabe, and K Kinoshita, and M Asano, and K Nakauchi, and K Fujita, and Y Nishimura, and H Nitoh, and M Yokoyama
Reproductive performance of Holstein cows administered GnRH analog HOE 766 (Buserelin) 26 to 34 days postpartum.
July 1985, Journal of animal science,
T Niijima, and K Isurugi, and K Kawabe, and K Kinoshita, and M Asano, and K Nakauchi, and K Fujita, and Y Nishimura, and H Nitoh, and M Yokoyama
Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration.
July 1983, Journal of steroid biochemistry,
T Niijima, and K Isurugi, and K Kawabe, and K Kinoshita, and M Asano, and K Nakauchi, and K Fujita, and Y Nishimura, and H Nitoh, and M Yokoyama
Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome.
January 1985, The Prostate,
T Niijima, and K Isurugi, and K Kawabe, and K Kinoshita, and M Asano, and K Nakauchi, and K Fujita, and Y Nishimura, and H Nitoh, and M Yokoyama
Sensitivity of luteinizing hormone and gonadal steroid responses to single intranasal administration of an LHRH agonist (Hoe-766) in young normal adult men.
January 1982, Journal of endocrinological investigation,
T Niijima, and K Isurugi, and K Kawabe, and K Kinoshita, and M Asano, and K Nakauchi, and K Fujita, and Y Nishimura, and H Nitoh, and M Yokoyama
A preliminary report on the comparative use of buserelin (Hoe 766) and danazol in the treatment of endometriosis: the University of Southern California experience.
January 1986, Progress in clinical and biological research,
T Niijima, and K Isurugi, and K Kawabe, and K Kinoshita, and M Asano, and K Nakauchi, and K Fujita, and Y Nishimura, and H Nitoh, and M Yokoyama
[Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
January 1986, Annales d'urologie,
T Niijima, and K Isurugi, and K Kawabe, and K Kinoshita, and M Asano, and K Nakauchi, and K Fujita, and Y Nishimura, and H Nitoh, and M Yokoyama
Administration of nasal Buserelin as compared with subcutaneous Buserelin implant for endometriosis.
July 1989, Fertility and sterility,
Copied contents to your clipboard!